Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes?

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease. The severity of airflow limitation, traditionally used to guide therapy in patients with COPD, does not describe this complexity properly. As a result, over the past few years there has been a great deal of interest in characterizing COPD more precisely and identifying homogeneous groups of patients who respond to specific therapeutic interventions (i.e., phenotypes). This review summarizes a presentation at the Transatlantic Airway Conference held in Lucerne on January 31, 2013 on this topic. It addresses the following questions: (1) What do we mean by "phenotypes"? (2) Why do we care about them? (3) Are phenotypes the best strategy to understand COPD heterogeneity? and (4) How can we progress in this field?

[1]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[2]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[3]  T. Wilkinson.  From disease heterogeneity through patient endotype to "microtype": the future for chronic obstructive pulmonary disease research? , 2012, American journal of respiratory and critical care medicine.

[4]  Thierry Troosters,et al.  Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality , 2012, PloS one.

[5]  Alvar Agusti,et al.  The COPD control panel: towards personalised medicine in COPD , 2012, Thorax.

[6]  Rudi Balling,et al.  Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.

[7]  Weiliang Qiu,et al.  Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. , 2012, Human molecular genetics.

[8]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[9]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[10]  A. Baccarelli,et al.  Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. , 2012, American journal of respiratory and critical care medicine.

[11]  L. Edwards,et al.  A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. , 2012, Human molecular genetics.

[12]  L. Edwards,et al.  A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19 q 13 , 2012 .

[13]  A. Barabasi,et al.  Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[14]  B. Celli,et al.  Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation , 2011, European Respiratory Journal.

[15]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[16]  J. Vestbo,et al.  Current controversies and future perspectives in chronic obstructive pulmonary disease. , 2011, American journal of respiratory and critical care medicine.

[17]  L. Hood,et al.  Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.

[18]  B. Celli,et al.  Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. , 2011, American journal of respiratory and critical care medicine.

[19]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[20]  J. Vestbo,et al.  Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. , 2010, American Journal of Respiratory and Critical Care Medicine.

[21]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[22]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[23]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[24]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[25]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[26]  Judith Garcia-Aymerich,et al.  Phenotypic Characterization and Course of Chronic Obstructive Pulmonary Disease in the PAC-COPD Study: Design and Methods , 2009 .

[27]  J. Garcia-Aymerich,et al.  Caracterización fenotípica y evolución de la EPOC en el estudio PAC-COPD: diseño y metodología , 2009 .

[28]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[29]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[30]  A. Feinberg.  Phenotypic plasticity and the epigenetics of human disease , 2007, Nature.

[31]  C. Sabatti,et al.  The Human Phenome Project , 2003, Nature Genetics.

[32]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[33]  P. Roe,et al.  Pulmonary disease , 1991 .